Related Experiment Video
Updated: Jul 19, 2026
09:55
Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
Published on: October 4, 2024
Evidence-based decision making in small animal therapeutics
Deborah T Kochevar1, Virginia Fajt
1College of Veterinary Medicine and Biomedical Sciences, 4461 Texas A&M University, College Station, TX 77843-4461, USA. deborah.kochevar@tufts.edu
The Veterinary Clinics of North America. Small Animal Practice
|September 21, 2006
Summary
Evidence-based veterinary medicine (EBVM) offers significant benefits for animal patients and the veterinary profession. Clinical pharmacologists are well-equipped to lead the adoption of EBVM practices.
Area of Science:
- Veterinary Medicine
- Evidence-Based Practice
- Clinical Pharmacology
Background:
- The increasing availability of evidence-based resources necessitates their adoption in veterinary practice.
- Evidence-Based Veterinary Medicine (EBVM) presents a framework for improving animal healthcare.
- The veterinary community is encouraged to embrace EBVM principles.
Purpose of the Study:
- To advocate for the adoption of evidence-based veterinary medicine.
- To highlight the readiness of clinical pharmacologists to implement EBVM.
- To emphasize the benefits of EBVM for patient care and professional advancement.
Main Methods:
- This commentary synthesizes the current landscape of evidence-based resources in veterinary medicine.
- It identifies the skills of clinical pharmacologists relevant to EBVM.
- It argues for the integration of EBVM into academic and clinical settings.
Main Results:
- Clinical pharmacologists possess the requisite skills for effective EBVM implementation.
- Adopting an evidence-based approach can significantly benefit animal patients.
- EBVM contributes to the overall advancement of the veterinary profession.
Conclusions:
- The veterinary field should actively embrace evidence-based veterinary medicine.
- Clinical pharmacologists are ideally positioned to champion and implement EBVM.
- The adoption of EBVM promises enhanced patient outcomes and professional growth.
Related Concept Videos
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:13Therapeutic Index
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...